MX345788B - Nuevo tratamiento del carcinoma de prostata. - Google Patents

Nuevo tratamiento del carcinoma de prostata.

Info

Publication number
MX345788B
MX345788B MX2013001272A MX2013001272A MX345788B MX 345788 B MX345788 B MX 345788B MX 2013001272 A MX2013001272 A MX 2013001272A MX 2013001272 A MX2013001272 A MX 2013001272A MX 345788 B MX345788 B MX 345788B
Authority
MX
Mexico
Prior art keywords
plumbagin
treatment
combination therapy
prostate carcinoma
naphthoquinone
Prior art date
Application number
MX2013001272A
Other languages
English (en)
Other versions
MX2013001272A (es
Inventor
Per Borgström
Original Assignee
Pellficure Pharmaceuticals Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pellficure Pharmaceuticals Inc * filed Critical Pellficure Pharmaceuticals Inc *
Publication of MX2013001272A publication Critical patent/MX2013001272A/es
Publication of MX345788B publication Critical patent/MX345788B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)

Abstract

En este documento se dan a conocer análogos de naftoquinona, tales como plumbagina, una composición farmacéutica que incluye análogos de naftoquinona tales como plumbagina, y métodos de tratamiento de enfermedades y/o afecciones tales como cáncer con análogos de naftoquinona, tales como plumbagina. Además son incluidas combinaciones de terapias en donde un análogo de naftoquinona, tal como plumbagina, y un agente de terapia hormonal son proporcionados a un sujeto que padece de una afección tal como el cáncer.
MX2013001272A 2010-08-04 2011-08-03 Nuevo tratamiento del carcinoma de prostata. MX345788B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37053410P 2010-08-04 2010-08-04
PCT/US2011/046474 WO2012018948A2 (en) 2010-08-04 2011-08-03 Novel treatment of prostate carcinoma

Publications (2)

Publication Number Publication Date
MX2013001272A MX2013001272A (es) 2013-05-22
MX345788B true MX345788B (es) 2017-02-15

Family

ID=44504259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001272A MX345788B (es) 2010-08-04 2011-08-03 Nuevo tratamiento del carcinoma de prostata.

Country Status (11)

Country Link
US (5) US9132105B2 (es)
EP (1) EP2600855A2 (es)
JP (1) JP5998137B2 (es)
KR (3) KR101926320B1 (es)
CN (1) CN103124563B (es)
AU (1) AU2011285724B2 (es)
BR (1) BR112013002655A2 (es)
CA (1) CA2807149C (es)
IL (1) IL224370B (es)
MX (1) MX345788B (es)
WO (1) WO2012018948A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX345788B (es) 2010-08-04 2017-02-15 Pellficure Pharmaceuticals Inc * Nuevo tratamiento del carcinoma de prostata.
CN102617664A (zh) * 2012-04-14 2012-08-01 广西师范大学 白花丹素-5-o-葡萄糖及其合成方法和应用
WO2013164683A1 (en) * 2012-04-30 2013-11-07 King Abdullah University Of Science And Technology Anti-cancer lead molecule
KR101388776B1 (ko) 2012-07-31 2014-04-23 성균관대학교산학협력단 2，3―비스［（2―하이드록시에틸）티오］―1，4―나프토퀴논을 포함하는 항염증용 조성물
SI3305285T1 (sl) * 2012-09-26 2021-03-31 Aragon Pharmaceuticals, Inc. Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka
WO2014060358A1 (en) * 2012-10-15 2014-04-24 Chamaeleo Pharma Bvba Fosfestrol for use in curative or palliative treatment of cancer in female mammals
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014158875A1 (en) * 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
CA2905649A1 (en) * 2013-03-15 2014-09-18 The Penn State Research Foundation Compositions and methods including celecoxib and plumbagin relating to treatment of cancer
AU2015314772B2 (en) * 2014-09-12 2020-02-27 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
WO2016135633A1 (en) * 2015-02-24 2016-09-01 King Abdullah University Of Science & Technology Cholesteryl ester transfer protein (cetp) inhibition in the treatment of cancer
ES2863500T3 (es) 2015-04-10 2021-10-11 Capsugel Belgium Nv Formulaciones lipídicas de acetato de abiraterona
WO2017070448A1 (en) * 2015-10-22 2017-04-27 The Trustees Of The University Of Pennsylvania 2-beta-naphthyl-acetic acid analogs as akr1c3 inhibitors and methods of using same
EP3528799A1 (en) * 2016-10-24 2019-08-28 Pellficure Pharmaceuticals, Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione
MX2019006593A (es) 2016-12-06 2019-09-13 Ic Medtech Corp Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas.
WO2018195202A1 (en) * 2017-04-21 2018-10-25 Pellficure Pharmaceuticals Inc. Compositions and methods for the treatment of cancer
KR101990054B1 (ko) * 2017-04-25 2019-06-17 대구대학교 산학협력단 로손을 유효성분으로 포함하는 항암 조성물
JOP20200076A1 (ar) 2017-10-16 2020-04-30 Aragon Pharmaceuticals Inc مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
CN107879958B (zh) * 2017-10-30 2019-07-19 黑龙江八一农垦大学 2-(4-甲氧基苯巯基)-5,8-二甲氧基-1,4-萘醌及其制备方法和含其的药物
CN108645927A (zh) * 2018-05-03 2018-10-12 四川农业大学 一种利用hplc测定蓝花丹中白花丹素含量的方法
ES2811674B2 (es) 2018-06-06 2024-02-07 Ic Medtech Corp Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitario para el tratamiento de una enfermedad parasitaria
CA3132623A1 (en) * 2019-03-06 2020-09-10 The Regents Of The University Of Michigan Substituted bicyclic and tetracyclic quinones and related methods of use
CN113134007B (zh) * 2020-01-20 2024-01-30 鲁南制药集团股份有限公司 一种醋酸阿比特龙口服制剂及其制备方法
CN113133984A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种cyp17抑制剂的制剂
WO2023220117A1 (en) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3431236A1 (de) 1984-08-24 1986-02-27 Carnivora-Deutschland GmbH, 7109 Jagsthausen Verwendung von 1,4-naphthochinon-derivaten in niedrigen konzentrationen zur immunstimulation
ZA882717B (en) 1987-04-22 1988-10-17 Merrell Dow Pharmaceuticals Inc. 17beta-(cyclopropylamino)-androst-5-eb-3beta-ol and related compounds useful as c17-20 lyase inhibitors
US4966898A (en) 1989-08-15 1990-10-30 Merrell Dow Pharmaceuticals Inc. 4-substituted 17β-(cyclopropylamino)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5457102A (en) 1994-07-07 1995-10-10 Janssen Pharmaceutica, N.V. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives
ATE186913T1 (de) 1992-03-31 1999-12-15 Btg Int Ltd 17-substituierte steroide, verwendbar bei behandlung von krebs
CN1095275A (zh) * 1993-05-13 1994-11-23 江远辉 一种治疗前列腺增生的注射液
GB9310635D0 (en) 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds
CN1131944A (zh) 1993-09-30 1996-09-25 山之内制药株式会社 唑类衍生物和它的药物组合物
CA2173729C (en) 1993-10-27 2001-05-15 Norton P. Peet .delta.16 unsaturated c17 heterocyclic steroids useful as steroid c17-20 lyase inhibitors
WO1996014090A1 (en) 1994-11-07 1996-05-17 Janssen Pharmaceutica N.V. Compositions comprising carbazoles and cyclodextrins
AU6015796A (en) 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
HUP0004037A3 (en) 1997-10-02 2002-03-28 Daiichi Seiyaku Co Novel dihydronaphthalene compounds and process for producing the same
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
AU3534699A (en) 1998-04-23 1999-11-08 Takeda Chemical Industries Ltd. Naphthalene derivatives, their production and use
WO2003027096A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors
JP4502641B2 (ja) 2002-01-24 2010-07-14 ティルタン ファーマ リミテッド 抗癌組み合わせおよびその使用方法
DE50214603D1 (de) 2002-12-28 2010-09-30 Gradl Grams Marianne Verfahren sowohl als stoff zur spezifischen proliferationsförderung von cd4+ lymphozyten durch eine kombination von alginat mit an hochdisperse kieselsaeure gekoppeltem curcumin
US20060111318A1 (en) 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
GB0324483D0 (en) 2003-10-21 2003-11-19 Psi Medica Ltd Composite material
WO2005053609A2 (en) * 2003-11-26 2005-06-16 Guilford Pharmaceuticals Inc. Methods of nad+-dependent deacetylase inhibitors
CN101037447B (zh) 2006-03-17 2010-09-08 广西师范大学 以白花丹素为配体的金属配合物、其合成方法及其用途
EP2034835B1 (en) 2006-06-16 2019-05-15 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
EP2086546B1 (en) 2006-11-21 2013-07-10 Viamet Pharmaceuticals, Inc. Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties
AU2009223653B2 (en) 2008-03-10 2014-07-31 University Of Louisville Research Foundation, Inc. Methods and compositions for controlled delivery of phytochemical agents
GB2514957A (en) 2009-02-05 2014-12-10 Tokai Pharmaceuticals Inc Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
AR078228A1 (es) 2009-06-26 2011-10-26 Novartis Ag Inhibidores de cyp17
CA2785898C (en) 2009-12-31 2018-07-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
AU2011239432A1 (en) 2010-04-16 2012-10-25 Colby Pharmaceutical Company Androgen induced oxidative stress inhibitors
HUE026474T2 (en) 2010-04-24 2016-06-28 Viamet Pharmaceuticals Inc Metalloenzyme inhibitor compounds
MX345788B (es) * 2010-08-04 2017-02-15 Pellficure Pharmaceuticals Inc * Nuevo tratamiento del carcinoma de prostata.
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US8389543B2 (en) 2010-11-13 2013-03-05 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
WO2012158884A1 (en) 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer
WO2014158875A1 (en) 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
AU2015314772B2 (en) 2014-09-12 2020-02-27 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma

Also Published As

Publication number Publication date
US20180116977A1 (en) 2018-05-03
KR20180010346A (ko) 2018-01-30
US20180296500A1 (en) 2018-10-18
CA2807149A1 (en) 2012-02-09
KR101594660B1 (ko) 2016-02-16
US9655868B2 (en) 2017-05-23
MX2013001272A (es) 2013-05-22
KR20130099928A (ko) 2013-09-06
JP2013532733A (ja) 2013-08-19
JP5998137B2 (ja) 2016-09-28
BR112013002655A2 (pt) 2016-05-31
AU2011285724A1 (en) 2013-03-21
US9132105B2 (en) 2015-09-15
KR101823275B1 (ko) 2018-03-08
US20170258744A1 (en) 2017-09-14
WO2012018948A3 (en) 2012-10-26
KR20160010889A (ko) 2016-01-28
US9877932B2 (en) 2018-01-30
AU2011285724B2 (en) 2015-01-22
EP2600855A2 (en) 2013-06-12
US10245240B2 (en) 2019-04-02
KR101926320B1 (ko) 2018-12-06
CN103124563B (zh) 2016-08-10
US20130219528A1 (en) 2013-08-22
CN103124563A (zh) 2013-05-29
CA2807149C (en) 2017-05-02
IL224370B (en) 2018-04-30
WO2012018948A2 (en) 2012-02-09
US20150352060A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
MX2013001272A (es) Nuevo tratamiento del carcinoma de prostata.
MX346147B (es) Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.
JO3606B1 (ar) معدل مستقبل الأندروجين في توليفة مع أسيتات أبراتيرون وبريدنيزون لعلاج سرطان البروستاتا
MX2019010601A (es) Terapia de combinacion para tratar cancer.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
PH12014501560A1 (en) Carbamate compounds and of making and using same
IN2012MN02591A (es)
MX349004B (es) Nuevos compuestos.
GB201118656D0 (en) New compounds
AU2011328009A8 (en) Compounds and methods for treating pain
MX366899B (es) Nuevos compuestos.
WO2011017534A3 (en) Treatment of prostate cancer
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MY180613A (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
IN2012DN02471A (es)
MX336761B (es) Compuestos para el tratamiento de cancer.
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
MX356317B (es) Tratamiento de síntomas asociados a gastroparesia femenina.
SA515360377B1 (ar) نظائر خيمرية من سوماتوستاتين- دوبامين
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
WO2012158933A3 (en) Macrocycllc therapeutic agents and methods of treatment
WO2012158776A3 (en) Combination therapy for treatment of cancer
GB201206984D0 (en) New therapeutic use
MX351961B (es) Analogos de diazonamida.
MX2018003308A (es) Suministro localizado de agente anti-fuctactico para tratamiento del cancer.

Legal Events

Date Code Title Description
FG Grant or registration